Skip to main content

Advertisement

SpringerLink
Log in

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rich TA, Shepard RC, Mosley ST (2004) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214–2232

    Article  CAS  PubMed  Google Scholar 

  2. Lockshin A, Danenberg PV (1981) Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30:247–257

    Article  CAS  PubMed  Google Scholar 

  3. Milano G, Etienne MC, Renée N, Thyss A, Schneider M, Ramaioli A, Demard F (1994) Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291–1295

    Article  CAS  PubMed  Google Scholar 

  4. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281

    Article  CAS  PubMed  Google Scholar 

  5. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16:1795–1802

    Article  CAS  PubMed  Google Scholar 

  6. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019

    CAS  PubMed  Google Scholar 

  7. Liang X, Yan Y, Wang L, Song G, DI L, Jiang H, Wang C, Li H (2015) First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients Oncol Lett 9: 987–993

  8. Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ, Osterwalder B, Verweij J, Twelves C (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22–29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  Google Scholar 

  10. Beslija S, Obralic N, Basic H, Tatarevic A, Naila M, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B (2006) Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 24(Suppl 18):571

    Google Scholar 

  11. Chan S, Romieu G, Huober J, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Antón A, Harrison M, Jones A, Carrasco E, Thareau Vaury A, Frimodt-Moller B, Fumoleau B (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753–1760

    Article  CAS  PubMed  Google Scholar 

  12. Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O’Shaughnessy J, Tjulandin S, NO16853 trial group (2012) Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol 23:589–597

    Article  CAS  PubMed  Google Scholar 

  13. Vici P, Giotta F, Di Lauro L, Sergi D, Vizza E, Mariani L, Latorre A, Pizzuti L, D’Amico C, Giannarelli D, Colucci G (2011) A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study. Oncology 81:230–236

    Article  CAS  PubMed  Google Scholar 

  14. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963–4970

    Article  CAS  PubMed  Google Scholar 

  15. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 24 (Suppl 18): 570

  16. Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V, Breast Cancer Investigators of the Hellenic Oncology Research Group (2010) Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as firstline treatment in women with advanced breast cancer. Ann Oncol 21:48–54

    Article  CAS  PubMed  Google Scholar 

  17. Michalaki V, Gennatas S, Gennatas K (2009) Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anti-Cancer Drugs 20:204–207

    Article  CAS  PubMed  Google Scholar 

  18. Seidman AD, Brufsky A, Ansari RH, Hart LL, Stein RS, Schwartzberg LS, Stewart JF, Russell CA, Chen SC, Fein LE, De La Cruz Vargas JA, Kim SB, Cavalheiro J, Zhao L, Gill JF, Obasaju CK, Orlando M, Tai DF (2011) Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol 22:1094–1101

    Article  CAS  PubMed  Google Scholar 

  19. Bachelot T, Bajard A, Ray-Coquard I, Provencal J, Coeffic D, Agostini C, Boisseau M, Kaphan R, Dramais D, Oprea C, Ferri-Dessens RM, Guastalla JP, Perol D (2011) Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. Oncology 80:262–268

    Article  CAS  PubMed  Google Scholar 

  20. Yu J, Lj DI, Song G, Che L, Hf J, Zhu YI, Liang X, Jia J, Zhang J, Yang H, Wang XI, Xn Z, Ren J (2011) Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer. Beijing Da Xue Xue Bao 43:151–156

    PubMed  Google Scholar 

  21. Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK (2004) Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 22:2321–2327

    Article  CAS  PubMed  Google Scholar 

  22. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O’Shaughnessy JA (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24:4384–4390

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, 6720, Hungary

    Renáta Kószó, Dóra Sántha & Zsuzsanna Kahán

  2. Borsod-Abauj-Zemplén County Hospital, Szentpéteri kapu 72-76, Miskolc, 3526, Hungary

    László Büdi

  3. Szabolcs-Szatmár-Bereg County Jósa András Hospital, Szent István u. 68, Nyíregyháza, 4400, Hungary

    József Erfán

  4. Kaposi Mór Teaching Hospital, Tallián Gy. u. 20-32, Kaposvár, 7400, Hungary

    Károly Győrfy

  5. Medical Center, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary

    Zsolt Horváth

  6. 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, Budapest, 1125, Hungary

    Judit Kocsis

  7. Uzsoki Hospital, Uzsoki u. 29-41, Budapest, 1145, Hungary

    László Landherr

  8. National Institute of Oncology, Ráth György u. 7-9, Budapest, 1126, Hungary

    Erika Hitre

  9. Zala County Hospital, Zrínyi M. u. 1, Zalaegerszeg, 8900, Hungary

    Károly Máhr

  10. Bács-Kiskun County Hospital, Nyíri u. 38, Kecskemét, 6000, Hungary

    Gábor Pajkos

  11. Hungarian Army Medical Center, Róbert Károly körút 44, Budapest, 1134, Hungary

    Zsuzsanna Pápai

Authors
  1. Renáta Kószó
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dóra Sántha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. László Büdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. József Erfán
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Károly Győrfy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zsolt Horváth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Judit Kocsis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. László Landherr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Erika Hitre
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Károly Máhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gábor Pajkos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zsuzsanna Pápai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Zsuzsanna Kahán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zsuzsanna Kahán.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kószó, R., Sántha, D., Büdi, L. et al. Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study. Pathol. Oncol. Res. 23, 505–511 (2017). https://doi.org/10.1007/s12253-016-0129-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-016-0129-7

Keywords

Search

Navigation